Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 3
2004 1
2005 2
2006 4
2007 3
2008 3
2009 2
2010 2
2013 6
2014 6
2015 2
2016 4
2017 1
2018 5
2019 7
2020 9
2021 3
2022 4
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
Acute myeloid leukaemia.
Khwaja A, Bjorkholm M, Gale RE, Levine RL, Jordan CT, Ehninger G, Bloomfield CD, Estey E, Burnett A, Cornelissen JJ, Scheinberg DA, Bouscary D, Linch DC. Khwaja A, et al. Nat Rev Dis Primers. 2016 Mar 10;2:16010. doi: 10.1038/nrdp.2016.10. Nat Rev Dis Primers. 2016. PMID: 27159408 Review.
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.
de Botton S, Fenaux P, Yee K, Récher C, Wei AH, Montesinos P, Taussig DC, Pigneux A, Braun T, Curti A, Grove C, Jonas BA, Khwaja A, Legrand O, Peterlin P, Arnan M, Blum W, Cilloni D, Hiwase DK, Jurcic JG, Krauter J, Thomas X, Watts JM, Yang J, Polyanskaya O, Brevard J, Sweeney J, Barrett E, Cortes J. de Botton S, et al. Among authors: khwaja a. Blood Adv. 2023 Jul 11;7(13):3117-3127. doi: 10.1182/bloodadvances.2022009411. Blood Adv. 2023. PMID: 36724515 Free PMC article.
Molecular MRD status and outcome after transplantation in NPM1-mutated AML.
Dillon R, Hills R, Freeman S, Potter N, Jovanovic J, Ivey A, Kanda AS, Runglall M, Foot N, Valganon M, Khwaja A, Cavenagh J, Smith M, Ommen HB, Overgaard UM, Dennis M, Knapper S, Kaur H, Taussig D, Mehta P, Raj K, Novitzky-Basso I, Nikolousis E, Danby R, Krishnamurthy P, Hill K, Finnegan D, Alimam S, Hurst E, Johnson P, Khan A, Salim R, Craddock C, Spearing R, Gilkes A, Gale R, Burnett A, Russell NH, Grimwade D. Dillon R, et al. Among authors: khwaja a. Blood. 2020 Feb 27;135(9):680-688. doi: 10.1182/blood.2019002959. Blood. 2020. PMID: 31932839 Free PMC article. Clinical Trial.
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, Morgan YG, Lok J, Grech A, Jones G, Khwaja A, Friis L, McMullin MF, Hunter A, Clark RE, Grimwade D; UK National Cancer Research Institute Acute Myeloid Leukaemia Working Group. Burnett AK, et al. Among authors: khwaja a. Lancet Oncol. 2015 Oct;16(13):1295-305. doi: 10.1016/S1470-2045(15)00193-X. Epub 2015 Sep 14. Lancet Oncol. 2015. PMID: 26384238 Clinical Trial.
Utility of 18F-FDG-PET/CT in lymphoblastic lymphoma.
Fox TA, Carpenter B, Taj M, Perisoglou M, Nicholson E, Castleton A, Elliot J, Uttenthal B, Wright C, Halsey R, Khwaja A, Grandage V, Mansour MR, Fielding AK, Hough R. Fox TA, et al. Among authors: khwaja a. Leuk Lymphoma. 2021 Apr;62(4):1010-1012. doi: 10.1080/10428194.2020.1855346. Epub 2020 Dec 4. Leuk Lymphoma. 2021. PMID: 33275056 No abstract available.
Optimising SARS-CoV-2 pooled testing for low-resource settings.
Majid F, Omer SB, Khwaja AI. Majid F, et al. Among authors: khwaja ai. Lancet Microbe. 2020 Jul;1(3):e101-e102. doi: 10.1016/S2666-5247(20)30056-2. Epub 2020 Jun 8. Lancet Microbe. 2020. PMID: 32835337 Free PMC article. No abstract available.
Optimising care for UK patients with acute myeloid leukaemia.
Pagliuca A, Khwaja A, Dillon R, Evans PA, Mohite U. Pagliuca A, et al. Among authors: khwaja a. Br J Hosp Med (Lond). 2022 Aug 2;83(8):42-50. doi: 10.12968/hmed.2022.0229. Epub 2022 May 27. Br J Hosp Med (Lond). 2022. PMID: 36066288 Free article.
Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation.
Iland HJ, Russell N, Dillon R, Schuh AC, Tedjaseputra A, Wei A, Khwaja A, Knapper S, Lane SW, Reynolds J, McMullin MF, Martin A, Tan P, Taussig DC, Wong A, Taper J, Fraga C, Kelly R, Tawana K, Mehta P, Mina A, Altman JK, Mølle I, Tauro S, Tholouli E. Iland HJ, et al. Among authors: khwaja a. Blood Adv. 2023 Jun 13;7(11):2580-2585. doi: 10.1182/bloodadvances.2022007126. Blood Adv. 2023. PMID: 36075018 Free PMC article. No abstract available.
60 results